Burjeel Cancer Institute inauguration ushers new era of cancer care in the UAE

UAE – Burjeel Holdings, a leading super-speciality healthcare services provider in MENA, has inaugurated the Burjeel Cancer Institute (BCI) in Mohammed bin Zayed City, Abu Dhabi.

This new facility was launched by Sheikh Nahyan bin Mubarak Al Nahyan, Minister of Tolerance and Coexistence, and will consolidate one of the largest cancer care networks in the UAE.

Notable figures attended the launch ceremony, including Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings; John Sunil, CEO of Burjeel Holdings; Omran Al Khoori, Executive Board Member of Burjeel Holdings; Safeer Ahamed, Group COO of Burjeel Holdings; and Aysha Al Mahri, Deputy CEO of Burjeel Medical City.

 Additionally, a delegation from the Department of Health—Abu Dhabi (DoH), medical staff, cancer survivors, and their families were present.

This institute will be headed by the accomplished Emirati oncologist Prof. Humaid Al Shamsi.

Located within Burjeel Medical City, the institute aims to offer advanced cancer treatments for patients in the UAE and beyond.

Speaking during the inauguration, Sheikh Nahyan highlighted that the UAE, under the directives of President His Highness Sheikh Mohamed bin Zayed Al Nahyan, is committed to providing the best healthcare and medical services to all.

He emphasized that caring for cancer patients in the UAE is a top priority and that the foundation of a prosperous society lies in the health and well-being of its people.

Furthermore, Sheikh Nahyan committed to advancing medical knowledge and ensuring the highest healthcare standards, particularly in cancer care, where the focus is on early diagnosis and implementing the most effective treatments.

He stressed the importance of sustaining the fight against cancer by addressing any delays in translating clinical discoveries and innovations into available treatments.

He believes increasing public confidence in advanced diagnostic and treatment services is crucial.

Sheikh Nahyan also highlighted the need for cooperation between multiple stakeholders in confronting a global challenge such as cancer.

He added, “The facilities hosted by the UAE, such as the BCI, reflect our dedication to providing comprehensive and innovative care for cancer patients. Their unique vision includes not only treatment but also prevention, early detection, and patient education.”

On his part, Dr. Shamsheer Vayalil, Founder and Chairman of Burjeel Holdings, mentioned that the launch of BCI marks a significant milestone in their journey to provide world-class cancer care within the UAE.

He reaffirmed their commitment to ensuring that patients receive the best possible care, supported by advanced technology and research. Dr. Vayalil believes that BCI will transform cancer treatment and significantly improve patient outcomes.

Commenting on the facility, Prof. Humaid Al Shamsi, CEO of Burjeel Cancer Institute, said that BCI is a hub of hope, capable of offering comprehensive and holistic cancer care.

By integrating advanced diagnostic tools and cutting-edge treatments under one roof, they aim to provide a seamless and patient-centric experience.

According to Prof. Al Shamsi, their focus is on enhancing the quality of life for patients and their families.

As the center of Burjeel’s cancer care network, BCI comprises Abu Dhabi, Al Ain, Al Dhafra, Sharjah, and Dubai facilities.

Annually, the network caters to over 5,000 oncology patients, performs over 10,000 screenings, and conducts over 10,000 radiotherapy sessions with the expertise of over 50 specialists.

BCI’s dedicated tower offers state-of-the-art facilities across four floors, featuring private chemotherapy suites, specialty clinics, a dedicated breast cancer unit, and patient-centric amenities.

It integrates chemotherapy, immunotherapy, surgical oncology, stereotactic radiosurgery (SRS), and stereotactic body radiotherapy (SBRT) to offer a seamless experience for patients.

Moreover, the institute offers cutting-edge treatments such as targeted therapy, precision medicine, advanced surgical techniques, and state-of-the-art radiation therapy, as well as AI-driven cancer diagnosis and management.

BCI incorporates advanced diagnostic capabilities through OncoHelix-CoLab to perform specialized tests locally and utilize technologies like Next-Generation Sequencing (NGS), Droplet Digital PCR, and Multi-color Flow Cytometry.

This integration is expected to enhance diagnostic precision and efficiency, leading to improved patient outcomes.

Additionally, BCI is equipped to conduct high-quality clinical trials and translational research, fostering advancements in cancer understanding and treatment.

Collaborations with international cancer research institutions and pharmaceutical companies are expected to pave the way for patients to access the latest innovations in cancer care.

For all the latest healthcare industry news from Africa and the World, subscribe to our NEWSLETTER, and YouTube Channel, follow us on Twitter and LinkedIn, and like us on Facebook